Artificial intelligence in drug development: present status and future prospects

被引：358
作者：
Mak, Kit-Kay [1 ,2 ]
Pichika, Mallikarjuna Rao [2 ,3 ]
机构：
[1] Int Med Univ, Sch Postgrad Studies & Res, Kuala Lumpur, Malaysia
[2] Int Med Univ, Sch Pharm, Dept Pharmaceut Chem, Kuala Lumpur, Malaysia
[3] Int Med Univ, IRDI, Ctr Bioact Mol & Drug Delivery, Kuala Lumpur, Malaysia
来源：
DRUG DISCOVERY TODAY | 2019年 / 24卷 / 03期
关键词：
PHARMACOLOGICAL-PROPERTIES; DEEP; GENERATION; DISCOVERY; DESIGN; TARGET; IDENTIFICATION; PRINCIPLES; REDUCE; HIT;
D O I：
10.1016/j.drudis.2018.11.014
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
Artificial intelligence (AI) uses personified knowledge and learns from the solutions it produces to address not only specific but also complex problems. Remarkable improvements in computational power coupled with advancements in AI technology could be utilised to revolutionise the drug development process. At present, the pharmaceutical industry is facing challenges in sustaining their drug development programmes because of increased R&D costs and reduced efficiency. In this review, we discuss the major causes of attrition rates in new drug approvals, the possible ways that AI can improve the efficiency of the drug development process and collaboration of pharmaceutical industry giants with AI-powered drug discovery firms.
引用
收藏
页码：773 / 780
页数：8
相关论文
共 72 条
  • [1] ACE revisited: A new target for structure-based drug design
    Acharya, KR
    Sturrock, ED
    Riordan, JF
    Ehlers, MRW
    [J]. NATURE REVIEWS DRUG DISCOVERY, 2003, 2 (11) : 891 - 902
  • [2] Alanine A, 2003, COMB CHEM HIGH T SCR, V6, P51
  • [3] Deep Learning Applications for Predicting Pharmacological Properties of Drugs and Drug Repurposing Using Transcriptomic Data
    Aliper, Alexander
    Plis, Sergey
    Artemov, Artem
    Ulloa, Alvaro
    Mamoshina, Polina
    Zhavoronkov, Alex
    [J]. MOLECULAR PHARMACEUTICS, 2016, 13 (07) : 2524 - 2530
  • [4] Anderson AC, 2012, METHODS MOL BIOL, V823, P359, DOI 10.1007/978-1-60327-216-2_23
  • [5] [Anonymous], BMC GENOMICS S1
  • [6] [Anonymous], 2016, NAT REV DRUG DISCOV
  • [7] [Anonymous], 2018, DRUG TARGET REV
  • [8] Use of a Novel Artificial Intelligence Platform on Mobile Devices to Assess Dosing Compliance in a Phase 2 Clinical Trial in Subjects With Schizophrenia
    Bain, Earle E.
    Shafner, Laura
    Walling, David P.
    Othman, Ahmed A.
    Chuang-Stein, Christy
    Hinkle, John
    Hanina, Adam
    [J]. JMIR MHEALTH AND UHEALTH, 2017, 5 (02):
  • [9] Artificial intelligence in neurodegenerative disease research: use of IBM Watson to identify additional RNA-binding proteins altered in amyotrophic lateral sclerosis
    Bakkar, Nadine
    Kovalik, Tina
    Lorenzini, Ileana
    Spangler, Scott
    Lacoste, Alix
    Sponaugle, Kyle
    Ferrante, Philip
    Argentinis, Elenee
    Sattler, Rita
    Bowser, Robert
    [J]. ACTA NEUROPATHOLOGICA, 2018, 135 (02) : 227 - 247
  • [10] Model-based machine learning
    Bishop, Christopher M.
    [J]. PHILOSOPHICAL TRANSACTIONS OF THE ROYAL SOCIETY A-MATHEMATICAL PHYSICAL AND ENGINEERING SCIENCES, 2013, 371 (1984):
12345678